This summary describes an article published in the medical journal Frontiers in Oncology in September 2023. The article reports results from a study that looked at breast cancer treatments for older patients aged 75 years or older. The study focused on a type of cancer called HR+/HER2- metastatic breast cancer. HR+/HER2- stands for hormone receptor-positive/human epidermal growth factor receptor 2-negative. This study evaluated whether older patients with this type of cancer benefited from the combination of two medicines – palbociclib and an aromatase inhibitor – compared with taking an aromatase inhibitor alone.This Plain Language Summary of Publication article (PLSP) from Future Oncology summarises the results from a study that looked at breast cancer treatments for older patients aged 75 years or older. The study focused on a type of cancer called HR+/HER2- metastatic breast cancer and evaluated whether older patients with this type of cancer benefited from the combination of two medicines – palbociclib and an aromatase inhibitor – compared with taking an aromatase inhibitor alone.

Visit the site using the link to read the article.

This PLSP is based on an articles called ‘Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older’. The article was published in the journal Frontiers in Oncology. 

Visit the Frontiers site using the link to read the article.